Cancer Advances, Inc., is a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers and other cancers. The company is focused on impacting human health and preventing the progression of these cancers by enhancing the adaptive immune system.
The company’s lead compound, Polyclonal Antibody Stimulator (PAS) vaccine, is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, colorectal, and liver. PAS already has been studied in multiple clinical trials, in over 1,500 subjects, and has demonstrated an excellent safety and tolerability profile.
Cancer Advances exclusively owns PAS and is focused on developing PAS therapeutics for gastric, pancreatic and other cancers, and identifying synergy between treatment classes. The company has cultivated an intellectual property portfolio that holds over 100 United States and worldwide patents related to PAS. In addition, Cancer Advances has a trademark portfolio and strategy for pursuing other trademarks.
Cancer Advances, Inc. is a wholly owned subsidiary of Cato BioVentures and is led by a seasoned management team with more than 100 years of combined industry experience.
Meet Our Team
Allen Cato, Chief Executive Officer and Chief Medical Officer
Allen Cato, M.D., Ph.D. cofounded CatoResearch and Cato BioVentures and has more than 40 years of experience in clinical study design, regulatory interactions, adverse drug reactions, and clinical research and new drug development. He has directed or participated in the development of more than 100 INDs and NDAs. Dr. Cato has published more than 100 papers, principally in the field of clinical pharmaceutical research, and he participates as a member of the board of directors for several pharmaceutical and biotechnology companies.
Lynda Sutton, President
Lynda Sutton, B.S. currently serves as the President and Chief Regulatory Officer for Cato Research, and President for Cancer Advances. Ms. Sutton has 25 years of experience in the drug development industry, specializing in the development of regulatory strategies for drugs and biologics. She has coordinated activities in various disciplines and has been involved in the development of new clinical entities, has overseen the preparation of FDA pre-meeting submissions, and has ensured that regulatory requirements necessary for the approval and launch of new products have been satisfied. She has served as the primary regulatory contact for more than 100 Biotech and pharmaceutical companies over the last 19 years. In addition, Ms. Sutton has cofounded several small biotechnology companies and serves as a member of the board of directors for several companies. She has expertise in the development of biological products, with emphasis on gene therapy and blood products, and in the development of oncological, anti-infective, and neuropharmacological products.
John Wingen, CFO
John Wingen has extensive operational and leadership experience, having served in executive leadership roles for over 25 years. For the last 10 years John has served in finance and operational roles in the drug development industry. John has extensive experience both buying and selling companies and raising investment funds.
Jo Cato, Ph.D., Vice President of Drug Development
Dr. Jo Cato serves as Vice President of Drug Development for Cancer Advances. Dr. Cato has more than 30 years experience in drug development, with expertise in drug metabolism and mathematical modeling, clinical pharmacokinetic study design, data analysis and reporting, preclinical pharmacokinetics, and toxicokinetics. He served as a pharmacokineticist for several life science companies including Abbott Laboratories and Ligand Pharmaceuticals as well as Cato Research/CATO SMS. He has previously served as an executive and in managing rolls over the past several years for Cato Research and is currently serving as Vice President for Cato BioVentures.
Jill P. Smith, M.D., Director of Clinical Gastroenterology and Oncology
Jill P. Smith, M.D., Director of Clinical Gastroenterology and Oncology for Cato Research, is a clinician scientist who is Board certified in Gastroenterology. She is a leading researcher in the field of Pancreatology and former President of the American Pancreas Association. She is the recipient of the European Basic Science research award for pancreas research. Dr. Smith served as the Director of Clinical and Translational Research in NIDDK at the National Institutes of Health until January 2014. As an independent researcher she has expertise in bench to bedside translational research, and FDA regulation. In October 2013 she served as the Moderator of the FDA GREAT-2 conference on conducting clinical trials in gastrointestinal disorders. Currently she is Full Professor at Georgetown University in Washington DC in the Department of Medicine, Division of Gastroenterology & Hepatology.
Teresa Phillips, Director of Development
Teresa Phillips is an experienced bench chemist (synthetic, medicinal, analytical, bioanalytical) with assortment of project management skills obtained over 25+ years of working in small biotechs. Highlights include synthetic experience in discovery, process development and manufacturing paradigms; extensive experience in analytical/bioanalytical method development and validation; product identification and qualification procedures; broad knowledge of GLP/GMP requirements needed for FDA approvals.
Katy Kuipers, Director of Business Development
Katy Kuipers is an experienced pharmaceutical professional with strong track record operating within large global organizations, life science start-ups, and pharmaceutical consulting organizations. 19+ years of experience includes: Business Development and Licensing (BD&L), Corporate/Commercial Planning and Strategy, and Alliance Management (AM). Past affiliations include Eisai Inc and OSI Pharmaceuticals.
© 2020 Cancer Advances, Inc. All rights reserved.